Peter Greenberg: Research
Dr. Peter Greenberg's laboratory and clinical interests have centered on improving the understanding of the biology, prognosis and treatment of myeloid clonal hemopathies such as myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).
Dr. Greenberg coordinated the International MDS Risk Analysis Workshop whose aim was collaborative biological and clinical approaches in MDS. This collaboration generated the current International Prognostic Scoring System (IPSS) for MDS. Dr. Greenberg is a member of the Board of Directors of the MDS Foundation.
He was honored in 1997 by being awarded the J.P. McCarthy International Prize for the most outstanding research in MDS. He is currently Chairman of the National Comprehensive Cancer Network (NCCN) Panel on MDS Treatment Guidelines and is a member of the Leukemia Core Committee of ECOG. His work with ECOG includes the role of Principal Investigator and co-Principal Investigator of several national clinical trials treating MDS and AML.
Dr. Greenberg's laboratory research focuses on evaluating altered hemopoietic regulation in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) by determining the differential expression of the array of regulatory genes in bone marrow hemopoietic precursor and stem cells from patients with differing stages of MDS and AML using microarray technology. These investigations have recently demonstrated differential gene expression profiles in MDS versus normal bone marrow stem cells as well as showing differences of molecular signatures in MDS patients with differing clinical stages and outcomes. These studies are aimed at defining critical gene profiles which could provide targets for treating these disorders.
Dr. Greenberg's clinical research has focused on developing novel and bio-selective approaches for treating MDS and refractory hematologic malignancies. In the Stanford Myelodysplastic Syndrome Center, of which he is Director, for anemic MDS patients he currently coordinates therapeutic clinical trials with the marrow erythroid stimulant darbopoetin, the anti-inflammatory compound Scios-469 and for patients with iron overload, the iron chelating agent deferasirox (Exjade). For higher risk MDS patients, he is beginning trials with the hypomethylating agents azacytidine or decitabine in combination with the histone deacetylating drug MS275, under the aegis of the Eastern Cooperative Oncology Group (ECOG), a study for which Dr. Greenberg is national co-Principle Investigator, or the platelet stimulating compound AMG531.
Click here for publications